News

Fierce Biotech4d
The trouble with TIGITs: How 'overenthusiasm' led to Big Pharma's risky $6B gamble
Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...
The Lancet5d
180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase ...
aNational Institute for Health and Care Research Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, UK bFaculty of Medicine ...